Pre-Clinic Model in Gynecologic Oncology: Past, Present, and Future

The field of gynaecologic oncology has seen increasing recognition of pre-clinic assessment and organisational frameworks as cornerstones of high-quality, patient-centred care. The intricate diagnostic and therapeutic pathways for cancers such as ovarian, endometrial, cervical, and vulvar demand seamless integration of multiple disciplines, timely interventions, and coordinated patient management. Traditional reactive care models, where patient navigation commences only after specialist consultation, are increasingly viewed as insufficient, prompting leading organisations like European Society of Gynaecological Oncology (ESGO), International Gynaecologic Cancer Society (IGCS), and Society of Gynaecologic Oncology (SGO) to advocate for proactive referral systems, robust multidisciplinary structures, and enhanced pre-operative assessment. Despite consensus on their value, implementation remains variable and results are not easily generalisable due to differences in health system resources, patient populations, and local infrastructure. Emerging frameworks incorporate digital triage, remote assessment tools, and artificial intelligence, showcasing promising pilot results but also highlighting significant gaps around interoperability, consistency, and real-world impact.Evidence from institutional case studies and national networks indicates that structured pre-clinic interventions, including triaging algorithms, pre-booked diagnostic workups, multidisciplinary tumour board pre-review, and patient education, can contribute to reduced delays, improved care allocation, and heightened patient preparedness. Nonetheless, the literature is marked by heterogeneity in study design, outcome measures, and reporting standards, hindering the synthesis of generalisable conclusions or best practice models. Furthermore, the translation of society-endorsed pathways into routine clinical practice frequently results in interpretational variability and limited rigorous evaluation. The uptake of novel digital and virtual navigation platforms introduces new questions about efficacy, safety, and equity, particularly in resource-constrained or digitally underserved settings.This Research Topic aims to critically examine the full spectrum of pre-clinic assessment models and organisational frameworks in gynaecologic oncology, exploring their design, implementation, and outcomes across diverse service contexts. It seeks to address fundamental questions about operational fidelity, sustainability, transferability, and patient-centred value of these interventions while aligning with international recommendations and standards. Submissions are encouraged to present original data, comparative analyses, or innovative theoretical models that assess both successes and challenges in translating organisational frameworks into improved care processes and outcomes.To gather further insights in optimising and evaluating pre-clinic frameworks in gynaecologic oncology across diverse health system settings, we welcome articles addressing, but not limited to, the following themes:- Clinical efficacy and operational feasibility of pre-clinic interventions.- Alignment and interpretation of ESGO, IGCS, or SGO recommendations in clinical pathways.- Patient-reported outcomes and the psychosocial impact of new pre-clinic models.- Economic implications, workforce considerations, and resource allocation.- Equity and access issues across geographic, digital, and socioeconomic divides.- Implementation science approaches with mapping of barriers, facilitators, and real-world adaptation.Eligible article types include original research, health services evaluations, systematic or scoping reviews, qualitative or mixed-methods analyses, quality improvement studies, pragmatic case reports, and multi-institutional comparative audits. Cross-national collaborations are particularly encouraged.Please note that manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of the scope of this Research Topic.Dr. Giannone is an invited speaker for Pharrma&.Dr. Osaria and Dr. Mangogna declared no conflicts of interest. Topic editors: Maria Orsaria, Alessandro Mangogna, Gaia Giannone Source: https://www.frontiersin.org/research-topics/77451/pre-clinic-model-in-gynecologic-oncology-past-present-and-future